{"type":"trials","record":{"id":86135,"source_id":"isrctn","external_id":"ISRCTN62749026","title":"A study to investigate if Levodopa (a Parkinson’s medication) can help people with wet age-related macular degeneration","brief_summary":"Co-Primary Objectives To evaluate the effects of 24 months (104 weeks) of L-DOPA in people newly diagnosed with wet AMD on: 1. Number of anti-VEGF injections required in the study eye over 24 months (104 weeks) 2. Best-corrected distance VA (BCdVA) (using Early Treatment Diabetic Retinopathy Study, ETDRS) at 24 months (104 weeks) in the study eye, tested for non-inferiority (five letter margin). To evaluate the effects of 24 months (104 weeks) of L-DOPA in people newly diagnosed with wet AMD on: 1. Best corrected distance VA (BCdVA) over time on study, measured with ETDRS charts 2. Retinal thickness 3. Disorganization of retinal layers 4. Presence/absence and quantity of retinal fluid 5. Fibrosis and atrophy 6. Generic health-related quality of life 7. Vision-specific quality of life 8. Health and social service resource use and participant non-health costs 9. Adverse events 10. Participant tolerability of study drug (nausea, dizziness & tiredness)","overall_status":"Not Yet Recruiting","phases":["Phase III"],"study_type":"Interventional","sponsor":"Belfast Health and Social Care Trust","enrollment":0,"countries":["United Kingdom","England"],"start_date":"2026-10-01","completion_date":"2030-04-30","last_update_date":"2026-09-01","source_url":"https://www.isrctn.com/ISRCTN62749026","editorial_summary":"A registered Phase III study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:45:21.717702+00:00","last_seen_at":"2026-09-26T12:27:04.896+00:00","metadata":{"sex":"All","age_range":"Mixed","comparator":null,"attribution":"Source: ISRCTN ISRCTN62749026; retrieved 2026-09-26","interventions":["Co-Careldopa [Levodopa + Carbidopa]","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":[],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration (nAMD)","• Levodopa 100mg / carbidopa 25mg - Active Arm 100mg L-DOPA+25mg carbidopa, orally, twice daily (morning and evening),…","Co-Careldopa [Levodopa + Carbidopa]","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-26T12:27:05.193853+00:00","duplicate_cluster_key":"id:isrctn62749026","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-10-01 to 2030-04-30","comparator":null,"confidence":"structured-source","population":"All · Mixed","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-26T12:27:04.897Z","intervention":["Co-Careldopa [Levodopa + Carbidopa]","Drug"],"participants":0,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase III","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":[],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/86135","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}